|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2003-10-1
|
|
pubmed:abstractText |
The near-universal emergence of imatinib resistance in patients with acute forms of Philadelphia chromosome-positive leukemia highlights the need for additional therapy to control this disease. G3139 (Genasense, oblimersen; Genta Inc.), a Bcl-2 antisense oligonucleotide, has been shown to down-regulate the Bcl-2 protein and induce apoptosis in myeloid leukemia cells from treated patients. We tested G3139 for its ability to inhibit BCR-ABL-mediated transformation in mice.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Fusion Proteins, bcr-abl,
http://linkedlifedata.com/resource/pubmed/chemical/Oligonucleotides, Antisense,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/Thionucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/imatinib,
http://linkedlifedata.com/resource/pubmed/chemical/oblimersen
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4267-73
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14519654-Animals,
pubmed-meshheading:14519654-Antineoplastic Agents,
pubmed-meshheading:14519654-Cell Division,
pubmed-meshheading:14519654-Cell Line, Tumor,
pubmed-meshheading:14519654-Drug Resistance, Neoplasm,
pubmed-meshheading:14519654-Fusion Proteins, bcr-abl,
pubmed-meshheading:14519654-Humans,
pubmed-meshheading:14519654-K562 Cells,
pubmed-meshheading:14519654-Leukemia, Myeloid,
pubmed-meshheading:14519654-Mice,
pubmed-meshheading:14519654-Mice, Nude,
pubmed-meshheading:14519654-Oligonucleotides, Antisense,
pubmed-meshheading:14519654-Piperazines,
pubmed-meshheading:14519654-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:14519654-Pyrimidines,
pubmed-meshheading:14519654-Survival Analysis,
pubmed-meshheading:14519654-Thionucleotides,
pubmed-meshheading:14519654-Time Factors,
pubmed-meshheading:14519654-Transplantation, Heterologous
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
|
|
pubmed:affiliation |
First Department of Internal Medicine, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan. tauchi@tokyo-med.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
